Top Markets
#1 DogBull DogBull +107.72%
#2 Siacoin Siacoin +53.43%
#3 ADO Protocol ADO Protocol +52.14%
#4 The Bitcoin Bull The Bitcoin Bull +40.37%
#5 MarsCoin MarsCoin +40.06%
#6 Ontology Gas Ontology Gas +22.96%
#7 Falcon Finance Falcon Finance +20.18%
#8 UnifAI Network UnifAI Network +19.65%
#9 Nockchain Nockchain +19.53%
#10 Apertum Apertum +18.08%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Classifica tra le azioni #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Prezzo delle azioni
$0.63963115
Ultima sincronizzazione: 2026-08-26
Capitalizzazione di mercato
$339.16M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-35.23%
Paese
CN
Scambia Jiangsu Recbio Technology Co., Ltd. (2179)

Categoria

Healthcare
Ricavi di Jiangsu Recbio Technology Co., Ltd. (2179)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Jiangsu Recbio Technology Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Jiangsu Recbio Technology Co., Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH